EpiLAB provides a handheld, battery‑operated device that performs a rapid, enzymatic TB screening test with electrochemical readout, delivering WHO‑level sensitivity without laboratory infrastructure. The system uses single‑use cartridges and a user‑friendly interface, enabling minimally trained operators in low‑resource settings to conduct large‑scale screening at low cost.
Funding
Funding not disclosed
Founders
Product
Problem
In many developing countries, tuberculosis diagnosis is limited by the need for laboratory infrastructure, trained personnel, and costly tests, resulting in a large proportion of cases remaining undetected and untreated.
Solution
EpiLAB offers a portable, battery‑operated screening test that can be performed without any laboratory setup. The device uses a patented enzymatic reaction combined with electrochemical detection to achieve WHO‑compliant sensitivity at a low cost. Its design allows minimally trained operators to conduct testing in community settings, improving case detection rates and helping to curb transmission in resource‑limited environments.
Target Audience
Primary customers are public health agencies, NGOs, and clinics operating in low‑resource regions that need rapid, low‑cost TB screening tools.
Features
- Battery‑powered, handheld reader requiring no external power or lab equipment
- Single‑use consumable cartridges with integrated enzymatic assay for TB biomarkers
- Electrochemical detection provides quantitative results comparable to standard laboratory tests
- User‑friendly interface that guides operators through the test without specialized training
- Reusable reader capable of processing up to 1,000 tests per unit, reducing per‑test cost
- Designed for affordability and scalability in low‑resource settings